Something remarkable happened in mental health science this week. While policy debates rage in Washington and budget fights threaten community programs, the laboratories and clinical trial sites are delivering. Two clusters of findings — one in ADHD, one in schizophrenia — stand out as genuine turning points.
A New Kind of ADHD Medicine, Finally Approved
On July 24, 2026, the FDA approved Simtriyo® (centanafadine) — a drug that works in a way no approved ADHD medication ever has. Every ADHD drug currently on the market either blocks the reuptake of dopamine and norepinephrine (stimulants like Adderall and Ritalin) or blocks norepinephrine alone (atomoxetine/Strattera). Simtriyo does something different: it inhibits reuptake of norepinephrine, dopamine, and serotonin simultaneously, making it the first-in-class norepinephrine-dopamine-serotonin reuptake inhibitor, or NDSRI. The FDA approved it for adults and children aged 6 and older (≥20 kg), based on four pivotal Phase 3 clinical trials.
Source: https://www.otsuka-us.com/otsuka-shares-fda-review-update-for-centanafadine
Why does the mechanism matter? Because the serotonin component may address symptoms that have always fallen through the cracks of standard ADHD treatment: emotional dysregulation, mood instability, and — critically — anxiety. Up to half of all adults with ADHD also have an anxiety disorder. Current stimulants can make anxiety worse. Clinicians have long cobbled together ADHD medications plus a separate SSRI for anxiety, with complicated results.
Simtriyo may change that calculus. A Phase 3b trial spotlighted this week at the Southern California Psychiatry Conference enrolled 315 adults with ADHD and comorbid anxiety — a population that prior ADHD trials had largely excluded. The drug met both its primary ADHD endpoint (significant symptom reduction vs. placebo by Week 1) and its key secondary anxiety endpoint on the Hamilton Anxiety Rating Scale (p=0.02). As Managed Healthcare Executive reported, “no therapy currently carries a US FDA indication for treating both conditions simultaneously.” These data aren’t yet on the Simtriyo label, but they significantly expand the evidence base.
Post-hoc analyses showed improvements in executive function — time management, task initiation, working memory. The drug has low abuse potential, giving families and clinicians an option without the controlled-substance baggage of stimulants.
Bottom line: For the roughly 22.5 million Americans living with ADHD, this is a meaningful new option — a genuinely new mechanism that may help people the existing drugs do not.
Schizophrenia’s Cognitive Fog: A New Target, a New Hope
Schizophrenia affects roughly two million Americans. Every approved antipsychotic targets dopamine receptors. They help with hallucinations and delusions. They do almost nothing for cognitive symptoms: disorganized thinking, impaired working memory, inability to plan or follow through. These deficits are why so many people with schizophrenia cannot hold jobs or live independently. They have been untreatable — until now, possibly.
The SEAD1 biomarker and drug candidate: Northwestern University’s Feinberg School of Medicine published a landmark study in Neuron identifying a novel biomarker and potential treatment for schizophrenia’s cognitive symptoms. By analyzing cerebrospinal fluid from 100+ patients and controls, researchers found a freely circulating form of a brain protein called Cacna2d1 that is significantly reduced in people with schizophrenia. The deficit allows brain circuits to become overexcited and poorly calibrated. The team engineered a synthetic version — SEAD1 — and in a genetic mouse model, a single injection corrected both the abnormal brain circuits and behavioral deficits, without observable side effects. The lead researcher’s vision: a weekly peptide injection, with a blood test first to identify which patients carry the biomarker — “almost like Ozempic for schizophrenia.”
Source: https://www.eurekalert.org/news-releases/1119907
The muscarinic pipeline expands: Psychiatric Times’ July 2026 pipeline review detailed the rapidly growing pipeline of muscarinic receptor treatments. Cobenfy (xanomeline-trospium) — the first antipsychotic in 70 years not to work through dopamine blockade — improves both positive and negative symptoms without metabolic side effects. New drugs in this class are in Phase 2 trials. A first-in-vivo PET imaging study this week found M1 receptor availability reduced 13–19% across brain regions in schizophrenia, strengthening the scientific case.
Source: https://clinicalmetric.com/insights/schizophrenia-clinical-trials-2026
Bottom line: People living with schizophrenia — and families and clinicians who support them — have waited decades for treatments that address the full disease. The research is delivering the most promising leads in a generation.
The Bigger Picture: Science Is Outpacing Stigma
The July 2026 APA journals published research on how redlining and discriminatory housing policy left measurable psychiatric damage across generations — a growing evidence base that mental illness is as much a social product as a biological one. Prevention and recovery are possible through policy, community investment, and structural change — not only through medicine.
The progress in ADHD and schizophrenia treatment is real. Breakthroughs in the lab create options that did not exist before — and every new option is a path forward for someone who had run out of them.
Pneumapsyche, Inc. monitors the mental and behavioral health field on behalf of the advocacy community. This post represents a synthesis of publicly available research and news as of August 3, 2026. It is not medical advice.